IP Library Granted Patent US 9,180,197
Granted Patent B2
US 9,180,197 · App. 14/490,034 · Granted Nov 10, 2015

Sustained delivery formulations of risperidone compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,180,197
App. No.
14/490,034
Granted
Nov 10, 2015
Kind
B2
Abstract

The present invention relates to a risperidone sustained release delivery system for treatment of medical conditions relating delusional psychosis, schizophrenia, bipolar disorder, psychotic depression, obsessive-compulsion disorder, Tourette syndrome, and autistic spectrum disorders. The sustained release delivery system includes a flowable composition containing risperidone, a metabolite, or a prodrug thereof and an implant containing risperidone, a metabolite, or a prodrug thereof. The flowable composition may be injected into tissue whereupon it coagulates to become the solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, an organic liquid, and risperidone, a metabolite, or a prodrug thereof.

Claims (10)

1. An injectable, flowable composition comprising

(a) about 15 wt % risperidone base in

(b) about 45 wt % of an 80/20 poly(DL-lactide-co-glycolide) biodegradable thermoplastic polyester with a terminal carboxy group having an average molecular weight of about 10,000 Daltons to about 50,000 Daltons; and

(c) about 55 wt % of N-methyl-2-pyrrolidone.

2. The composition of claim 1 , wherein the flowable composition is subcutaneously injectable.

3. The composition of claim 1 , wherein the flowable composition transforms into a solid implant in situ after contact with water, body fluid, or other aqueous medium.

4. The composition of claim 1 , wherein the flowable composition produces maximum plasma concentration (C max ) levels of risperidone within about 6 hours after injection into a patient.

5. The composition of claim 1 , wherein the flowable composition produces maximum plasma concentration (C max ) levels of risperidone within about 2 hours after injection into a patient.

6. The composition of claim 1 , wherein the biodegradable thermoplastic polyester has an average molecular weight of about 15,000 Daltons to about 40,000 Daltons.

7. The composition of claim 1 , wherein the biodegradable thermoplastic polyester has a polydispersity index of about 1.4 to about 2.0.

Assignments (8)
TERMINATION AND RELEASE OF SECURITY INTEREST Recorded Nov 11, 2024
From: MORGAN STANLEY SENIOR FUNDING, INC.
To: INDIVIOR UK LIMITED (F/K/A RB PHARMACEUTICALS LIMITED)
Reel/Frame 069322/0443 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 27, 2019
From: LINDEMANN, CHRISTOPHER; LI, QI
To: QLT USA, INC.
Reel/Frame 051133/0141 →
CHANGE OF ASSIGNEE ADDRESS Recorded May 21, 2019
From: INDIVIOR UK LIMITED
To: INDIVIOR UK LIMITED
Reel/Frame 049246/0785 →
CHANGE OF NAME Recorded Sep 21, 2015
From: RB PHARMACEUTICALS LIMITED
To: INDIVIOR UK LIMITED
Reel/Frame 036643/0841 →
CHANGE OF NAME Recorded Apr 30, 2015
From: QLT USA, INC.
To: TOLMAR THERAPEUTICS, INC.
Reel/Frame 035554/0964 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 29, 2015
From: DADEY, ERIC
To: QLT USA, INC.
Reel/Frame 035530/0266 →
GRANT OF SECURITY INTEREST IN PATENTS Recorded Dec 23, 2014
From: RB PHARMACEUTICALS LIMITED
To: MORGAN STANLEY SENIOR FUNDING, INC. AS COLLATERAL AGENT
Reel/Frame 034696/0885 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 1, 2014
From: TOLMAR THERAPEUTICS, INC.
To: RB PHARMACEUTICALS LIMITED
Reel/Frame 034291/0096 →